Literature DB >> 14993355

Expression array technology in the diagnosis and treatment of breast cancer.

Stefanie S Jeffrey1, Michael J Fero, Anne-Lise Børresen-Dale, David Botstein.   

Abstract

The most common group of cancers among American women involves malignancies of the breast. Breast cancer is a complex disease, involving several different types of tissues and specific cells with various functions, that is categorized into many distinct subtypes. Microarray analysis has recently revealed that different biological subtypes of breast cancer are accompanied by differences in their specific gene expression profile. Because breast tissue (and breast cancer) is heterogeneous, microarray analysis may provide clinicians with a better understanding of how to treat each specific case. Thus, microarray analysis may translate basic research data into more confident diagnoses, specifically designed treatment regimens geared to each patient's needs, and better clinical prognoses.

Entities:  

Mesh:

Year:  2002        PMID: 14993355     DOI: 10.1124/mi.2.2.101

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  10 in total

Review 1.  Gene expression profiling of breast cancer in ethnic populations: an aid to gene discovery for the benefit of all.

Authors:  Steve Goodison
Journal:  Breast J       Date:  2005 Mar-Apr       Impact factor: 2.431

Review 2.  Toward predictive models of mammalian cells.

Authors:  Avi Ma'ayan; Robert D Blitzer; Ravi Iyengar
Journal:  Annu Rev Biophys Biomol Struct       Date:  2005

3.  Critical evaluation of transcription factor Atf2 as a candidate modulator of alcohol preference in mouse and human populations.

Authors:  L S Wang; Y Jiao; Y Huang; X Y Liu; G Gibson; B Bennett; K M Hamre; D W Li; H Y Zhao; J Gelernter; H R Kranzler; L A Farrer; L Lu; Y J Wang; W K Gu
Journal:  Genet Mol Res       Date:  2013-11-26

4.  Additional prognostic factors in right colon cancer staging.

Authors:  Domenico Parmeggiani; Nicola Avenia; Adelmo Gubitosi; Francesco Gilio; Pietro Francesco Atelli; Massimo Agresti
Journal:  Updates Surg       Date:  2011-06-23

5.  Genomic dissection and prioritizing of candidate genes of QTL for regulating spontaneous arthritis on chromosome 1 in mice deficient for interleukin-1 receptor antagonist.

Authors:  Yanhong Cao; Jifei Zhang; Yan Jiao; Jian Yan; Feng Jiao; Xiaoyun Liu; Robert W Williams; Karen A Hasty; John M Stuart; Weikuan Gu
Journal:  J Genet       Date:  2012-08       Impact factor: 1.166

6.  Limitations of mRNA amplification from small-size cell samples.

Authors:  Vigdis Nygaard; Marit Holden; Anders Løland; Mette Langaas; Ola Myklebost; Eivind Hovig
Journal:  BMC Genomics       Date:  2005-10-27       Impact factor: 3.969

7.  Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations.

Authors:  Fagner Santos do Carmo; Eduardo Ricci-Junior; Cristal Cerqueira-Coutinho; Marta de Souza Albernaz; Emerson Soares Bernardes; Sotiris Missailidis; Ralph Santos-Oliveira
Journal:  Int J Nanomedicine       Date:  2016-12-19

8.  Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections.

Authors:  Monica I Ardura; Romain Banchereau; Asuncion Mejias; Tiziana Di Pucchio; Casey Glaser; Florence Allantaz; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Octavio Ramilo
Journal:  PLoS One       Date:  2009-05-08       Impact factor: 3.240

9.  Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis.

Authors:  Hongjuan Zhao; Trevor Hastie; Michael L Whitfield; Anne-Lise Børresen-Dale; Stefanie S Jeffrey
Journal:  BMC Genomics       Date:  2002-10-30       Impact factor: 3.969

10.  A method for detecting and correcting feature misidentification on expression microarrays.

Authors:  I-Ping Tu; Marci Schaner; Maximilian Diehn; Branimir I Sikic; Patrick O Brown; David Botstein; Michael J Fero
Journal:  BMC Genomics       Date:  2004-09-09       Impact factor: 3.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.